The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma

European Respiratory Journal

Volumn 25, Issue 2, 2005, Pages 289-294

  Straub, Daniel A ^a   Moeller, A ^a   Minocchieri, S ^a   Hamacher, J ^b   Sennhauser, F H ^a   Hall, G L ^a   Wildhaber, J H ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Asthma; Infant; Inflammation; Lung function test; Montelukast; Nitric oxide

Indexed keywords

MONTELUKAST; NITRIC OXIDE; PLACEBO;

ALLERGY; ARTICLE; ASTHMA; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAMILY HISTORY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; WHEEZING;

ACETATES; ADMINISTRATION, INHALATION; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; MALE; NITRIC OXIDE; PROSPECTIVE STUDIES; QUINOLINES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 13844275408     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00031904     Document Type: Article

References (37)

1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. N Engl J Med 1995; 332: 133-138.
2. Salmon B, Wilson NM, Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990; 65: 401-403.
3. Volovitz B, Soferman R, Blau H, Nussinovitch M, Varsano I. Rapid induction of clinical response with a short-term high-dose starting schedule of budesonide nebulizing suspension in young children with recurrent wheezing episodes. J Allergy Clin Immunol 1998; 101: 464-469.
4. Kharitonov SA, Yates D, Springall DR, et al. Exhaled nitric oxide is increased in asthma. Chest 1995; 107: Suppl. 3, 156S-157S.
5. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53: 91-95.
6. Byrnes CA, Dinarevic S, Shinebourne EA, Barnes PJ, Bush A. Exhaled nitric oxide measurements in normal and asthmatic children. Pediatr Pulmonol 1997; 24: 312-318.
7. Baraldi E, Azzolin NM, Zanconato S, Dario C, Zacchello F. Corticosteroids decrease exhaled nitric oxide in children with acute asthma. J Pediatr 1997; 131: 381-385.
8. Baraldi E, Dario C, Ongaro R, et al. Exhaled nitric oxide concentrations during treatment of wheezing exacerbation in infants and young children. Am J Respir Crit Care Med 1999; 159: 1284-1288.
9. Bisgaard H, Loland L, Oj JA. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 1999; 160: 1227-1231.
10. Carra S, Gagliardi L, Zanconato S, et al. Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children. Respir Med 2001; 95: 734-739.
11. Wildhaber JH, Moeller A, Hall GH, Sennhauser FH, Stick SM. Levels of exhaled nitric oxide in recurrently wheezy infants are decreased following inhaled steroid therapy. Schweiz Med Wochenschr 2000; 130: 529-534.
12. Wildhaber JH, Hall GL, Stick SM. Measurements of exhaled nitric oxide with the single-breath technique and positive expiratory pressure in infants. Am J Respir Crit Care Med 1999; 159: 74-78.
13. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533-1546.
14. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56: 7-11.
15. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-451.
16. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997; 62: 556-561.
17. Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA, et al. The efficacy of montelukast in the treatment of cat allergen-induced asthma in children. J Allergy Clin Immunol 2002; 109: 794-799.
18. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol 2002; 109: 257-263.
19. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-428.
20. Leigh R, Vethanayagam D, Yoshida M, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002; 166: 1212-1217.
21. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998; 279: 1181-1186.
22. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Paediatrics 2001; 108: E48.
23. Strauch E, Moske O, Thoma S, et al. A randomized controlled trial on the effect of montelukast on sputum eosinophil cationic protein in children with corticosteroid-dependent asthma. Pediatr Res 2003; 54: 198-203.
24. Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 2002; 20: 630-634.
25. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002; 20: 853-858.
26. Turner DJ, Stick SM, Lesouef KL, Sly PD, Lesouef PN. A new technique to generate and assess forced expiration from raised lung volume in infants. Am J Respir Crit Care Med 1995; 151: 1441-1450.
27. Noble V, Ruggins NR, Everard ML, Milner AD. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child 1992; 67: 285-288.
28. Kaditis AG, Gourgoulianis K, Winnie G. Anti-inflammatory treatment for recurrent wheezing in the first five years of life. Pediatr Pulmonol 2003; 35: 241-252.
29. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med 2000; 162: 1500-1506.
30. Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest 2002; 121: 732-738.
31. Bratton DL, Lanz MJ, Miyazawa N, White CW, Silkoff PE. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: a preliminary study. Pediatr Pulmonol 1999; 28: 402-407.
32. Moeller A, Franklin P, Hall GL, et al. Inhaled fluticasone dipropionate decreases levels of nitric oxide in recurrently wheezy infants. Pediatr Pulmonol 2004; 38: 250-255.
33. Hayden MJ, Wildhaber JH, LeSouef PN. Bronchodilator responsiveness testing using raised volume forced expiration in recurrently wheezing infants. Pediatr Pulmonol 1998; 26: 35-41.
34. Goldstein AB, Castile RG, Davis SD, et al. Bronchodilator responsiveness in normal infants and young children. Am J Respir Crit Care Med 2001; 164: 447-454.
35. Cane R, Ranganathan S, McKenzie S. What do parents of wheezy children understand by "wheeze"? Arch Dis Child 2000; 82: 327-332.
36. Wildhaber JH, Dore ND, Devadason SG, et al. Comparison of subjective and objective measures in recurrently wheezy infants. Respiration 2002; 69: 397-405.
37. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-1438.